Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Carmat    ALCAR   FR0010907956

CARMAT

(ALCAR)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
06/13/2019 06/14/2019 06/17/2019 06/18/2019 06/19/2019 Date
20.15(c) 20(c) 19.98(c) 19.82(c) 19.8(c) Last
2 132 5 218 2 513 2 815 8 711 Volume
-0.74% -0.74% -0.10% -0.80% -0.10% Change
More quotes
Financials (EUR)
Sales 2019 -
EBIT 2019 -46,7 M
Net income 2019 -42,9 M
Debt 2019 17,8 M
Yield 2019 -
Sales 2020 9,23 M
EBIT 2020 -49,4 M
Net income 2020 -33,5 M
Debt 2020 36,7 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 0
EV / Sales2020 24,3x
Capitalization 188 M
More Financials
Company
Carmat specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all... 
More about the company
Surperformance© ratings of Carmat
Trading Rating : Investor Rating :
More Ratings
Latest news on CARMAT
05/21CARMAT : Announces the Resumption of Production of Prostheses for the PIVOTAL St..
BU
04/12CARMAT : Announces a Delay in the Resumption of Production of Prostheses for the..
AQ
04/10CARMAT : Announces a Delay in the Resumption of Production of Prostheses for the..
BU
03/29CARMAT : the Shareholders' Meeting approves all of the resolutions supported by ..
BU
03/28CARMAT : to Present the Positive Interim Results of the First Part of the PIVOTA..
BU
02/13CARMAT : Reports Its 2018 Annual Results and Confirms Its 2019 Development Prosp..
BU
01/21CARMAT : 2019 Financial Calendar
BU
01/16CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
AQ
01/15CARMAT : presents positive interim results of the first part of its PIVOTAL stud..
BU
2018CARMAT : Juncker Plan - The EIB supports CARMAT with EUR 30m
AQ
More news
Analyst Recommendations on CARMAT
More recommendations
Sector news : Medical Devices & Implants
09:31aGLOBAL MARKETS LIVE : Viacom, Apple, Siemens, Boeing…
06/17ABBOTT LABORATORIES : Launches Rapid Point-of-Care HbA1c Test to Aid in Diabetes..
DJ
06/16ZIMMER BIOMET : Who stands to lose if Swiss-EU treaty talks fail
RE
06/13DHL says it will invest $150 million to expand U.S. healthcare business
RE
06/12U.S. pet doctors steel themselves for online pharmacy challenge
RE
More sector news : Medical Devices & Implants
Chart CARMAT
Duration : Period :
Carmat Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARMAT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 26,4 €
Spread / Average Target 31%
EPS Revisions
Managers
NameTitle
Stéphane Piat Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
Pascale d’Arbonneau Chief Financial & Administrative Officer
Marc Grimmé Director-Research & Development
Piet Jansen Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CARMAT-15.66%213
STRYKER CORPORATION25.29%68 415
SMITH & NEPHEW17.49%18 540
WRIGHT MEDICAL GROUP NV15.03%3 828
GLAUKOS CORP33.84%2 315
DOUBLE MEDICAL TECHNOLOGY INC--.--%1 831